# Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Malignancies

> **NCT00629473** · PHASE1 · COMPLETED · sponsor: **Celgene** · enrollment: 86 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** NPI-0052 on Days 1, 8, 15 every 28 days
- **DRUG:** NPI-0052 on Days 1, 4, 8, 11 every 21 days
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT00629473
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2017-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00629473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00629473, "Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Malignancies". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00629473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*